Avalo Therapeutics, Inc. (AVTX) Profit Margins
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVTXAvalo Therapeutics, Inc.Follow AVTX — free
—
Price chart with a free account
- Market cap
- 371.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 97.7% | 53.6% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | — | — | — | |
| Operating margin | 49.9% | -503.4% | -239.1% | -1087.4% | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% | — | |
| Net margin | 42.7% | -569.9% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% | — | |
| FCF margin | 45.1% | -52.5% | -287.3% | -606.1% | -1315.4% | -148.7% | -1594.6% | -11123.8% | -87216.9% | — |
USD millions · SEC XBRL
Every figure on this page comes from Avalo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.